Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 3 1

Status

Unknown 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 9Thoracic 4Dermatologic 2Sarcoma 1Genitourinary 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Brain Neoplasms 4Recurrence 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Radiosurgery 27Radiotherapy 17Magnetic Resonance Spectroscopy 14Erlotinib Hydrochloride 14Bevacizumab 13Pemetrexed 10Carboplatin 10pembrolizumab 9Gefitinib 9osimertinib 8icotinib 7Temozolomide 7Nivolumab 6Specimen Handling 5Paclitaxel 5Spermine Synthase 4Mental Status and Dementia Tests 4Ipilimumab 4Drug Therapy 4Cisplatin 4atezolizumab 3alectinib 3aflutinib 3Radiation 3Immunotherapy 3Fluorodeoxyglucose F18 3regorafenib 2paclitaxel-Angiopep-2 conjugate 2motexafin gadolinium 2epothilone B 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Brain Neoplasms × Spermine Synthase × Thoracic × Clear all
NCT06702826 2024-11-25

Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases

Xiangya Hospital of Central South University

Phase 2 Recruiting
20 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03075072 2024-10-23

Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial

Dana-Farber Cancer Institute

Phase NA Active not recruiting
196 enrolled
BreastCNSDermatologicGenitourinaryThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Melanoma, Recurrence

NCT03754530 2018-11-27

Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation

Betta Pharmaceuticals Co., Ltd.

Phase 2 Unknown
162 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT02972333 2016-11-23

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Shandong Cancer Hospital and Institute

Phase 3 Unknown
150 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡